cURL Error: Failed to connect to 217.15.170.3 port 80 after 1064 ms: Couldn't connect to servercURL Error: Failed to connect to 217.15.170.3 port 80 after 1067 ms: Couldn't connect to server Monitoring of BMY situation on January 13, 2025
Stocks Prognosis
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site

New Drug Approval Boosts BMY Stocks: Analysts Recommend Buying Bristol-Myers Squibb Shares

Published on January 13, 2025
Bristol-Myers Squibb Company (NYSE: BMY) experienced a significant rise in its stock value after the approval of a groundbreaking drug. The new medication, which has been developed to treat a rare form of cancer, has shown promising results in clinical trials. Analysts are now recommending investors to buy BMY shares, as they anticipate a surge in demand for the drug. With the growing prevalence of this type of cancer and the limited treatment options available, Bristol-Myers Squibb is expected to witness substantial revenue growth in the coming years. Stocks Prognosis, a leading financial advisory firm, suggests considering investing in Bristol-Myers Squibb as a part of a well-diversified portfolio for potential long-term gains.
Go to BMY Page

Investor opinions & comments

To leave a comment, you need to Login or Register.

There are no comments yet. Be the first to leave one!

Other Data for BMY

No other news found for this ticker.

Related Data

Is Bristol-Myers Squibb Company BMY the Best Pharma Stock to Buy According to Hedge Funds

March 18, 2025

Bristol Myers Squibb NYSE:BMY Set to Revolutionize Cancer Treatment with Breakthrough Drug

June 23, 2025

Stanley Lafferty, Founder of Stocks Prognosis, Recommends Buying Bristol-Myers Squibb Company BMY Shares

December 23, 2024

Bristol-Myers Squibb Announces Groundbreaking Cancer Treatment

December 10, 2024

Is Trending Stock Bristol Myers Squibb Company BMY a Buy Now?

January 6, 2025